Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Study Summary

Brief summary The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).

Conditions

Ulcerative Colitis (UC)

Interventions / Drugs

XmAb942 Placebo

View on ClinicalTrials.gov ↗

Sponsor

XNCR

Xencor Inc

Bispecific Antibodies

D38/100

Study Details

Enrollment270 participants

Primary Completion—

Lead SponsorXencor, Inc.

Data Retrieved2026-04-11 04:31:58.925902+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.